Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fecal Hemoglobin Stability Evaluated for FITs

By LabMedica International staff writers
Posted on 31 Oct 2017
Screening with guaiac-based fecal occult blood tests (gFOBT), followed by colonoscopy for patients who test positive, has been associated with a reduction of 15% to 33% in colorectal cancer (CRC)–related mortality.

Fecal immunochemical test (FIT) methods have been developed. These immunoassays form an antibody antigen complex with the globin moiety of human hemoglobin (Hb) to generate either an immunoturbidimetric signal, which can be measured quantitatively or by lateral-flow immunochromatographic analysis, a qualitative band that can be detected visually.

A large team of scientists collaborating with those at Sunnybrook Research Institute (Toronto, ON, Canada) implemented a novel, standardized method to compare Hb stability across various fecal immunochemical tests. The stability of Hb was analyzed in collection devices inoculated with Hb-spiked feces and (1) stored at various temperatures (frozen, refrigerated, ambient, and elevated) for more than 60 days; (2) after undergoing three controlled, freeze-thaw cycles; and (3) after being transported by courier or postal services in uncontrolled temperature conditions from three locations in Ontario, Canada, to a central testing center. The team compared the stability of Hb across five different immunochemical kits and one guaiac kit.

The scientists found that the stability of Hb varied with time and temperature and by kit. Lower Hb recoveries occurred with increasing temperature and increasing time from sample collection to testing. Refrigeration provided the best stability, although results varied across kits, from 4.2 days to more than 60 days before a pre-specified threshold with less than 70% probability of the test results remaining positive was reached.

Freeze-thaw stability varied across kits and cycles. Hb recoveries from Hemoglobin NS-Plus, was 91.7% to 95.4%; while for OC-Sensor Diana, the Hb recovery was 57.6% to 74.9%. Agreement regarding Hb levels before and after transportation varied across kits, from 57% to 100%. The scientists found that the Hema-Screen SPECIFIC, was the best performer among the qualitative kits.

The authors concluded that important differences in Hb stability were found across the included fecal immunochemical tests and these findings should inform practice-based and population-based colorectal cancer screening. The study was published on October 2, 2017, in the journal Archives Of Pathology & Laboratory Medicine.

Related Links:
Sunnybrook Research Institute


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.